Trulicity (Dulaglutide) Global Regulatory Status

FDA Approval and Initial US Label

The FDA approved dulaglutide on September 18, 2014, under New Drug Application (NDA) 125469, granting Eli Lilly market authorization for a once-weekly GLP-1 receptor agonist indicated as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes [1]. The approval covered two dose strengths: 0.75 mg and 1.5 mg.

Six AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) trials formed the backbone of the original submission. AWARD-1 (N=978) compared dulaglutide 1.5 mg against exenatide 10 mcg twice daily as add-on to metformin and pioglitazone; dulaglutide achieved a mean HbA1c reduction of 1.51% versus 0.99% for exenatide at 26 weeks [2]. AWARD-5 (N=1,098) tested dulaglutide head-to-head against sitagliptin 100 mg, showing a 1.10% HbA1c reduction with dulaglutide 1.5 mg compared to 0.39% with sitagliptin over 52 weeks [3]. The FDA's review noted that the safety profile was consistent with the GLP-1 receptor agonist class, with gastrointestinal events (nausea, diarrhea, vomiting) being the most commonly reported adverse reactions.

A black box warning for thyroid C-cell tumors was included from the outset. This warning states that dulaglutide causes dose-dependent thyroid C-cell tumors in rats, and that it is unknown whether it causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans [1]. Trulicity is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2.

Higher-Dose Approvals and Label Expansions

The initial US label covered 0.75 mg and 1.5 mg. Eli Lilly later pursued higher doses for patients needing greater glycemic control. The FDA approved the 3.0 mg dose in September 2020 and the 4.5 mg dose simultaneously, expanding the dosing range for patients who had not reached their HbA1c target on lower strengths [4].

The approval of these higher doses was supported by the AWARD-11 trial (N=1,842), which randomized patients already on dulaglutide 1.5 mg plus metformin to either 3.0 mg or 4.5 mg versus continued 1.5 mg. At 36 weeks, dulaglutide 4.5 mg reduced HbA1c by an additional 0.64% compared to 1.5 mg continuation, while the 3.0 mg dose achieved an additional 0.43% reduction [4]. Body weight loss was also dose-dependent. That trial confirmed no new safety signals at the higher doses, with gastrointestinal side effects remaining the primary tolerability concern.

The label does not currently include an obesity or weight-management indication. Dulaglutide's weight loss effect (approximately 3 to 5 kg at the 4.5 mg dose) is modest compared to semaglutide 2.4 mg, which produced 14.9% mean body weight reduction in the STEP-1 trial [5]. Eli Lilly has not publicly pursued a chronic weight management indication for dulaglutide.

REWIND Trial and Cardiovascular Indication

The most significant post-approval label expansion came from the REWIND trial (Researching Cardiovascular Events With a Weekly INcretin in Diabetes), a landmark cardiovascular outcomes trial published in The Lancet in 2019 [6]. REWIND stands apart from other GLP-1 receptor agonist cardiovascular trials for several reasons. It enrolled a broader population.

REWIND randomized 9,901 participants with type 2 diabetes across 24 countries. Median follow-up was 5.4 years, the longest among completed GLP-1 receptor agonist cardiovascular outcomes trials. Only 31.5% of participants had established cardiovascular disease at baseline, meaning the majority were enrolled on the basis of cardiovascular risk factors alone [6]. The primary composite endpoint of MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) occurred in 12.0% of the dulaglutide group versus 13.4% of the placebo group (HR 0.88; 95% CI 0.79 to 0.99; P=0.026).

Dr. Hertzel Gerstein, the principal investigator of REWIND and a professor at McMaster University, stated: "These results show that dulaglutide reduces cardiovascular events in a broad spectrum of people with type 2 diabetes, including those without prior cardiovascular disease" [6].

Based on REWIND, the FDA updated the Trulicity label in February 2020 to include a cardiovascular indication: reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [7]. This made dulaglutide the third GLP-1 receptor agonist (after liraglutide and semaglutide) to carry a cardiovascular risk-reduction indication in the US.

European Medicines Agency Authorization

The EMA granted marketing authorization for dulaglutide on November 21, 2014, through its centralized procedure, allowing commercial availability across all European Union member states [8]. The European Public Assessment Report (EPAR) reviewed the same AWARD clinical program submitted to the FDA.

The EMA-approved indication mirrored the FDA label at launch: treatment of adults with type 2 diabetes mellitus to improve glycemic control as monotherapy (when metformin is considered inappropriate) or in combination with other glucose-lowering agents including insulin [8]. Following publication of REWIND, the European Commission updated the dulaglutide Summary of Product Characteristics (SmPC) in November 2020 to include the cardiovascular data, though the European label presents this information in the clinical trial results section rather than as a standalone indication.

One distinction between US and EU labeling: the EMA label permits dulaglutide monotherapy when metformin is contraindicated or not tolerated, while the FDA label positions it as an adjunct to diet and exercise without specifying monotherapy eligibility [1][8]. This difference reflects a broader pattern in which EMA labels tend to define where a drug sits in the treatment algorithm more explicitly than FDA labels do.

Regulatory Status Across Asia-Pacific and Other Regions

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved dulaglutide in June 2015. The approved dose range in Japan initially included only 0.75 mg, reflecting the PMDA's conservative approach to GLP-1 receptor agonist dosing in a population with generally lower body weight [9]. The Japanese label has since been expanded.

Australia's Therapeutic Goods Administration (TGA) listed dulaglutide on the Australian Register of Therapeutic Goods in March 2015. The TGA approval covers the same indications as the FDA label, and dulaglutide is listed on the Pharmaceutical Benefits Scheme (PBS) for type 2 diabetes, making it available with government subsidy for eligible patients.

Health Canada approved dulaglutide in November 2015. The Canadian product monograph closely follows the FDA label, including the boxed warning about thyroid C-cell tumors [10]. Brazil's ANVISA, South Korea's MFDS, and multiple regulatory authorities across the Middle East and Latin America have also granted marketing authorizations. By 2023, Eli Lilly reported commercial availability in over 60 countries.

Post-Market Safety Surveillance and Signal Updates

Post-market surveillance has generated ongoing safety data beyond the pre-approval clinical trials. The FDA's Adverse Event Reporting System (FAERS) database and the Sentinel System have monitored several signals.

Acute pancreatitis remains a labeled risk for all GLP-1 receptor agonists, including dulaglutide. In REWIND, acute pancreatitis occurred in 0.3% of dulaglutide-treated patients versus 0.2% of placebo patients, a difference that was not statistically significant [6]. The 2023 Endocrine Society Clinical Practice Guideline on pharmacological management of obesity recommends that clinicians monitor for signs and symptoms of pancreatitis with all GLP-1 receptor agonists but notes that the absolute risk is low [11].

In 2022, the FDA required a label update for dulaglutide (and other GLP-1 receptor agonists) to include intestinal obstruction as a potential adverse reaction, based on post-marketing reports [12]. Ileus and intestinal obstruction had been reported at a rate sufficient for the FDA to determine that a causal relationship could not be excluded given the known effect of GLP-1 receptor agonists on gastrointestinal motility.

Dr. Michael Nauck, a professor at Ruhr University Bochum and a leading GLP-1 pharmacology researcher, has noted: "The gastrointestinal effects of GLP-1 receptor agonists, including slowed gastric emptying, are pharmacologically expected and generally manageable, but clinicians should be alert to rare complications like ileus in vulnerable patients" [13].

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) conducted a safety review of GLP-1 receptor agonists and thyroid cancer risk in 2023. The review concluded that available evidence did not confirm a causal association between GLP-1 receptor agonist use and thyroid cancer in humans, though the black box warning for MTC based on animal data remains on the label [14].

Patent Status and Biosimilar Outlook

Dulaglutide's core composition-of-matter patent in the United States (US Patent 7,521,530) expired in 2024. Device patents covering the Trulicity pen extend protection through 2025 to 2027, depending on the specific filing [15]. Eli Lilly's 2024 annual report acknowledged that biosimilar competition for Trulicity is expected within the next several years.

No biosimilar dulaglutide has yet received FDA or EMA approval as of May 2026. The FDA's biosimilar pathway (351(k) of the Public Health Service Act) requires demonstration of biosimilarity in analytical, preclinical, and clinical studies. Because GLP-1 receptor agonists are large-molecule biologics, the regulatory bar for biosimilar approval is higher than for generic small-molecule drugs like metformin.

Several manufacturers have disclosed biosimilar dulaglutide programs in regulatory filings, though none have reached the BLA (Biologics License Application) stage in the US. The European biosimilar pathway, administered through the EMA, may see earlier applications given the EU's longer track record with biosimilar approvals [8].

Current Prescribing Considerations Based on Regulatory Label

The FDA-approved prescribing information specifies a starting dose of 0.75 mg subcutaneously once weekly, with the option to increase to 1.5 mg, then 3.0 mg, and finally 4.5 mg if additional glycemic control is needed [1]. Each dose escalation should occur after at least four weeks on the current dose. Trulicity can be administered at any time of day, with or without meals, and the injection site should be rotated among the abdomen, thigh, and upper arm.

The 2024 American Diabetes Association (ADA) Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit (including dulaglutide) as preferred second-line agents in patients with type 2 diabetes and established atherosclerotic cardiovascular disease or high cardiovascular risk, independent of HbA1c [16]. The ADA framework positions dulaglutide as an option alongside liraglutide and subcutaneous semaglutide in this cardiovascular benefit category.

Renal dosing adjustments are not required for dulaglutide. REWIND included participants with an eGFR as low as 15 mL/min/1.73 m², and a prespecified renal secondary outcome showed a 15% reduction in the composite of new macroalbuminuria, sustained decline in eGFR of 30% or more, or chronic renal replacement therapy (HR 0.85; 95% CI 0.77 to 0.93) [6]. This renal data appears in the label's clinical studies section and supports use of dulaglutide in patients with moderate-to-severe chronic kidney disease.